Hutchison China MediTech (Chi-Med) has started a global Phase I/Ib trial of HMPL-689, the company's oral small molecule phosphoinositide-3 kinase delta isoform (PI3Kδ) inhibitor, enrolling patients with relapsed or refractory lymphoma. Chi-Med dosed the first patient on August 26, 2019 in the US. The lymphoma trial will run in parallel to a similar China Phase I/Ib trial that tests HMPL-689 in a broad range of hematological cancers. Chi-Med says the candidate is highly selective and potent. More details....
Stock Symbol: (AIM/NASDQ: HCM)
Share this with colleagues:
Original Article: Chi-Med Starts US-EU Trials of Oral Lymphoma Drug